{"id":915919,"date":"2025-12-03T16:08:51","date_gmt":"2025-12-03T21:08:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/"},"modified":"2025-12-03T16:08:51","modified_gmt":"2025-12-03T21:08:51","slug":"alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/","title":{"rendered":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08"},"content":{"rendered":"

<\/p>\n

Alto Neuroscience Announces New Employee Inducement Grants <\/b>Under NYSE Rule 303A.08<\/b><\/p>\n

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE<\/a>)–
\nAlto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto\u2019s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto\u2019s common stock. The stock option was granted under Alto\u2019s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08.\n<\/p>\n

\nThe stock option has an exercise price of $12.80 which is equal to the closing price of Alto\u2019s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remainder of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee\u2019s continued service to Alto on each vesting date.\n<\/p>\n

About Alto Neuroscience<\/b><\/p>\n

\nAlto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto\u2019s Precision Psychiatry Platform\u2122 measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto\u2019s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com<\/a> or follow Alto on X<\/a>.\n<\/p>\n

Availability of Information on Alto\u2019s Website<\/b><\/p>\n

\nAlto routinely uses its investor relations website<\/a> to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251203087055\/en\/<\/a><\/span><\/p>\n

Investor & Media Contact:
\n<\/b>
Nick Smith
\n
investors@altoneuroscience.com
\n<\/a>
media@altoneuroscience.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Mental Health Health Neurology Other Science Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto\u2019s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto\u2019s common stock. The stock option was granted under Alto\u2019s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08. The stock option has an exercise price of $12.80 which is equal to the closing price of Alto\u2019s common stock on the … <\/p>\n

Continue reading “Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915919","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto\u2019s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto\u2019s common stock. The stock option was granted under Alto\u2019s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08. The stock option has an exercise price of $12.80 which is equal to the closing price of Alto\u2019s common stock on the … Continue reading "Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T21:08:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08\",\"datePublished\":\"2025-12-03T21:08:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/\",\"name\":\"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-12-03T21:08:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/","og_locale":"en_US","og_type":"article","og_title":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","og_description":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Alto Neuroscience, Inc. (\u201cAlto\u201d) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto\u2019s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto\u2019s common stock. The stock option was granted under Alto\u2019s 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08. The stock option has an exercise price of $12.80 which is equal to the closing price of Alto\u2019s common stock on the … Continue reading \"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T21:08:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08","datePublished":"2025-12-03T21:08:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/","name":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-12-03T21:08:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203087055r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alto-neuroscience-announces-new-employee-inducement-grants-under-nyse-rule-303a-08\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915919"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915919\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}